Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 641

1.

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Gerhauser C, Favero F, Risch T, Simon R, Feuerbach L, Assenov Y, Heckmann D, Sidiropoulos N, Waszak SM, Hübschmann D, Urbanucci A, Girma EG, Kuryshev V, Klimczak LJ, Saini N, Stütz AM, Weichenhan D, Böttcher LM, Toth R, Hendriksen JD, Koop C, Lutsik P, Matzk S, Warnatz HJ, Amstislavskiy V, Feuerstein C, Raeder B, Bogatyrova O, Schmitz EM, Hube-Magg C, Kluth M, Huland H, Graefen M, Lawerenz C, Henry GH, Yamaguchi TN, Malewska A, Meiners J, Schilling D, Reisinger E, Eils R, Schlesner M, Strand DW, Bristow RG, Boutros PC, von Kalle C, Gordenin D, Sültmann H, Brors B, Sauter G, Plass C, Yaspo ML, Korbel JO, Schlomm T, Weischenfeldt J.

Cancer Cell. 2018 Dec 10;34(6):996-1011.e8. doi: 10.1016/j.ccell.2018.10.016.

PMID:
30537516
2.

Upregulation of centromere protein F is linked to aggressive prostate cancers.

Göbel C, Özden C, Schroeder C, Hube-Magg C, Kluth M, Möller-Koop C, Neubauer E, Hinsch A, Jacobsen F, Simon R, Sauter G, Michl U, Pehrke D, Huland H, Graefen M, Schlomm T, Luebke AM.

Cancer Manag Res. 2018 Nov 9;10:5491-5504. doi: 10.2147/CMAR.S165630. eCollection 2018.

3.

Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer.

Kluth M, Volta H, Hussein M, Taskin B, Frogh S, Möller-Koop C, Büscheck F, Jacobsen F, Tsourlakis MC, Lübke AM, Hinsch A, Clauditz T, Graefen M, Heinzer H, Huland H, Minner S, Sauter G, Wilczak W, Schlomm T, Simon R.

Cancer Manag Res. 2018 Nov 19;10:5909-5917. doi: 10.2147/CMAR.S172637. eCollection 2018.

4.

Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes.

Leyh-Bannurah SR, Zaffuto E, Dell'Oglio P, Tian Z, Moschini M, Capitanio U, Briganti A, Montorsi F, Fisch M, Chun F, Kachanov M, Budäus L, Graefen M, Huland H, Karakiewicz PI.

Urol Int. 2018 Nov 27:1-9. doi: 10.1159/000495071. [Epub ahead of print]

PMID:
30481764
5.

Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.

Tilki D, Chen MH, Wu J, Huland H, Graefen M, Braccioforte M, Moran BJ, D'Amico AV.

JAMA Oncol. 2018 Nov 15. doi: 10.1001/jamaoncol.2018.4836. [Epub ahead of print]

PMID:
30452521
6.

Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes.

Pompe RS, Leyh-Bannurah SR, Preisser F, Salomon G, Graefen M, Huland H, Karakiewicz PI, Tilki D.

Urol Oncol. 2018 Dec;36(12):527.e21-527.e28. doi: 10.1016/j.urolonc.2018.08.010. Epub 2018 Nov 12.

PMID:
30442538
7.

Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.

Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C.

Prostate. 2018 Nov 14. doi: 10.1002/pros.23736. [Epub ahead of print]

PMID:
30430607
8.

North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients.

Preisser F, Mazzone E, Nazzani S, Marchioni M, Bandini M, Tian Z, Saad F, Soulières D, Shariat SF, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Br J Cancer. 2018 Dec;119(12):1552-1556. doi: 10.1038/s41416-018-0323-3. Epub 2018 Nov 14.

PMID:
30425350
9.

Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer.

Löser A, Beyer B, Carl CO, Löser B, Nagaraj Y, Frenzel T, Petersen C, Krüll A, Graefen M, Schwarz R.

Strahlenther Onkol. 2018 Nov 2. doi: 10.1007/s00066-018-1380-5. [Epub ahead of print]

PMID:
30390115
10.

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.

Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; Cancer Genome Atlas Research Network, Camargo F, Liang H.

Cell Rep. 2018 Oct 30;25(5):1304-1317.e5. doi: 10.1016/j.celrep.2018.10.001.

11.

Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer.

Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, Shariat SF, Tian Z, Saad F, Montorsi F, Zorn KC, Graefen M, Tilki D, Karakiewicz PI.

Clin Genitourin Cancer. 2018 Oct 4. pii: S1558-7673(18)30581-0. doi: 10.1016/j.clgc.2018.09.024. [Epub ahead of print]

PMID:
30366880
12.

Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study.

Bandini M, Nazzani S, Marchioni M, Preisser F, Tian Z, Moschini M, Abdollah F, Suardi N, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

Clin Genitourin Cancer. 2018 Sep 22. pii: S1558-7673(18)30185-X. doi: 10.1016/j.clgc.2018.09.011. [Epub ahead of print]

PMID:
30342845
13.

High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.

Brandi F, Grupp K, Hube-Magg C, Kluth M, Lang D, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Jacobsen F, Huland H, Steurer S, Lebok P, Hinsch A, Wilczak W, Schlomm T, Simon R.

Oncol Lett. 2018 Nov;16(5):6238-6244. doi: 10.3892/ol.2018.9417. Epub 2018 Sep 7.

14.

The effect of race on survival after local therapy in metastatic prostate cancer patients.

Mazzone E, Bandini M, Preisser F, Nazzani S, Tian Z, Abdollah F, Soulieres D, Graefen M, Montorsi F, Shariat S, Saad F, Briganti A, Karakiewicz P.

Can Urol Assoc J. 2018 Oct 15. doi: 10.5489/cuaj.5399. [Epub ahead of print]

PMID:
30332592
15.

Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States.

Preisser F, Nazzani S, Mazzone E, Knipper S, Bandini M, Tian Z, Haese A, Saad F, Zorn KC, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI.

World J Urol. 2018 Oct 12. doi: 10.1007/s00345-018-2525-y. [Epub ahead of print]

PMID:
30315358
16.

Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery.

Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, Maurer T, Graefen M.

Eur Urol Focus. 2018 Oct 3. pii: S2405-4569(18)30286-4. doi: 10.1016/j.euf.2018.09.014. [Epub ahead of print]

PMID:
30292421
17.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R.

Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26.

18.

Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis.

Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Saad F, Chun FK, Shariat SF, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Int J Urol. 2018 Nov;25(11):929-936. doi: 10.1111/iju.13780. Epub 2018 Aug 26.

PMID:
30146729
19.

Comprehensive Characterization of Cancer Driver Genes and Mutations.

Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L.

Cell. 2018 Aug 9;174(4):1034-1035. doi: 10.1016/j.cell.2018.07.034. No abstract available.

20.

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.

Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C; Cancer Genome Atlas Research Network, Rätsch G.

Cancer Cell. 2018 Aug 13;34(2):211-224.e6. doi: 10.1016/j.ccell.2018.07.001. Epub 2018 Aug 2.

Supplemental Content

Loading ...
Support Center